- Home
- OLO vs SYRE Comparison
OLO vs SYRE Comparison
Compare OLO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- SYRE
- Stock Information
- Founded
- OLO 2005
- SYRE 2013
- Country
- OLO United States
- SYRE United States
- Employees
- OLO N/A
- SYRE N/A
- Industry
- OLO Major Banks
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- SYRE Health Care
- Exchange
- OLO Nasdaq
- SYRE Nasdaq
- Market Cap
- OLO 1.0B
- SYRE 841.4M
- IPO Year
- OLO 2021
- SYRE 2016
- Fundamental
- Price
- OLO $8.62
- SYRE $15.20
- Analyst Decision
- OLO Buy
- SYRE Buy
- Analyst Count
- OLO 3
- SYRE 6
- Target Price
- OLO $9.00
- SYRE $55.00
- AVG Volume (30 Days)
- OLO 1.3M
- SYRE 524.3K
- Earning Date
- OLO 07-30-2025
- SYRE 08-06-2025
- Dividend Yield
- OLO N/A
- SYRE N/A
- EPS Growth
- OLO N/A
- SYRE N/A
- EPS
- OLO 0.01
- SYRE N/A
- Revenue
- OLO $299,107,000.00
- SYRE N/A
- Revenue This Year
- OLO $20.21
- SYRE N/A
- Revenue Next Year
- OLO $17.90
- SYRE N/A
- P/E Ratio
- OLO $805.46
- SYRE N/A
- Revenue Growth
- OLO 23.31
- SYRE N/A
- 52 Week Low
- OLO $4.20
- SYRE $10.91
- 52 Week High
- OLO $9.78
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- OLO 52.76
- SYRE 51.60
- Support Level
- OLO $8.47
- SYRE $14.09
- Resistance Level
- OLO $8.94
- SYRE $18.01
- Average True Range (ATR)
- OLO 0.29
- SYRE 1.26
- MACD
- OLO -0.04
- SYRE -0.20
- Stochastic Oscillator
- OLO 47.53
- SYRE 39.66
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.